TY - JOUR
AU1 - Piepoli, Massimo F
AU2 - Corrà, Ugo
AU3 - Dendale, Paul
AU4 - Frederix, Ines
AU5 - Prescott, Eva
AU6 - Schmid, Jean Paul
AU7 - Cupples, Margaret
AU8 - Deaton, Christi
AU9 - Doherty, Patrick
AU1 - Giannuzzi, Pantaleo
AU1 - Graham, Ian
AU1 - Hansen, Tina Birgitte
AU1 - Jennings, Catriona
AU1 - Landmesser, Ulf
AU1 - Marques-Vidal, Pedro
AU1 - Vrints, Christiaan
AU1 - Walker, David
AU1 - Bueno, Héctor
AU1 - Fitzsimons, Donna
AU2 - Pelliccia, Antonio
AB - Abstract Worldwide, each year more than 7 million people experience myocardial infarction, in which one-year mortality rates are now in the range of 10%, but vary with patient characteristics. The consequences are even more dramatic: among patients who survive, 20% suffer a second cardiovascular event in the first year and approximately 50% of major coronary events occur in those with a previous hospital discharge diagnosis of ischaemic heart disease. The people behind these numbers spur this call for action. Prevention after myocardial infarction is crucial to reduce risk and suffering. Evidence-based interventions include optimal medical treatment with anti-platelets and statins, achievement of blood pressure, lipid and blood glucose targets, and appropriate lifestyle changes. The European Society of Cardiology and its constituent bodies are determined to embrace this challenge by developing a consensus document in which the existing gaps for secondary prevention strategies are reviewed. Effective interventions in relation to the patients, healthcare providers and healthcare systems are proposed and discussed. Finally, innovative strategies in hospital as well as in outpatient and long-term settings are endorsed. Cardiovascular prevention, myocardial infarction, cardiac rehabilitation, risk factors, pharmacological therapy, exercise training, healthcare systems Disease burden Worldwide, each year more than 7 million people experience acute myocardial infarction (AMI),1 and although substantial reductions in mortality have been experienced in recent decades,2 one-year mortality rates are still in the range of 10%,3 varying with patient characteristics. In the Swedish SCAAR registry one-year mortality rates were approximately 10% among patients aged 70–79 years and 24% among patients aged 80–90 years.4 The consequences of AMI are more dramatic: among patients who survive a AMI, 20% suffer a second cardiovascular event in the first year and approximately 50% of major coronary events occur in those with a previous hospital discharge diagnosis of AMI.5 While early events are related to ruptured coronary plaques and associated thrombosis, the majority of later events may be the result of coronary and systemic atherosclerosis progression. Thus it is being increasingly appreciated that evidence-based long-term management of ischaemic heart disease (IHD) is critical to achieve optimal reduction in mortality and morbidity.6 Prevention after AMI is a crucial part of this, and is associated with improved prognosis7,8 with evidence-based interventions, such as optimal medical treatment, appropriate lifestyle changes and cardiovascular risk factor control.9 Importantly, the impact of lifestyle change after AMI has a rapid onset: patients who adhere to exercise and diet recommendations have a 54% lower risk and smokers who quit smoking a 43% lower risk of recurrent events six months after AMI.10 Despite this compelling evidence, preventive care post AMI remains sub-optimal. Cross-sectional data from the serially conducted EUROASPIRE surveys across Europe in both patients with established IHD and people at high cardiovascular risk have demonstrated a high prevalence of unhealthy lifestyles, modifiable risk factors and inadequate use of drug therapies to achieve blood pressure and lipid goals. Most recently, in the fourth survey of coronary patients, after a median time of 1.35 years after their acute event, 48.6% of patients who were smoking at the time of their event persisted in smoking, little or no physical activity was reported in nearly two thirds of interviewees, over a third (37.6%) were obese, 42.7% had blood pressure ≥140/90 mmHg (≥140/80 in people with diabetes), 80.5% had low-density lipoprotein (LDL) cholesterol ≥1.8 mmol/L and in those with diabetes, glucose control was relatively poor, with less than half reaching the guideline target of haemoglobin A1c (HbA1c) of <7.0%.11 Similarly, an Italian multicentre registry study performed in 2010–2012 showed in 11,706 patients from 163 large-volume coronary care units, that at six months drug adherence was 90%, but the recommended targets of blood pressure (<140/90 mmHg) were reached in only 74%, LDL (<1.8 mmol/l) in 76%, HbA1c (<7% in treated people with diabetes) in 45% and smoking cessation only in 73% of the participant patients.12 Secondary prevention Secondary prevention programmes, defined as the level of preventive care focusing on early risk stratification, use of referral services and initiation of treatment to stop the progress of an established disease process, are highly recommended in all IHD patients, to restore quality of life, maintain or improve functional capacity and prevent recurrence.13 Cardiac rehabilitation, operationally defined here as a structured multidisciplinary intervention for cardiovascular risk assessment and management, advice on physical activity, psychosocial support and the appropriate prescription and adherence to cardioprotective drugs, is the most investigated modality of secondary prevention interventions,14 its core components in post-AMI patients well identified (Table 1).15 Table 1. Components of secondary prevention in post-AMI patients. Interventions . Components . Risk factor modification/ lifestyle interventions • Healthy diet • Physical activity • Weight control • Smoking cessation • Stop alcohol abuse Preventive medications • Antithrombotic therapies • Beta-blockers • ACE inhibitors/ARBs/ aldosterone antagonists (if depressed left ventricular function) • Statins Management of comorbidities • Obesity • Dyslipidaemia • Arterial hypertension • Diabetes • Heart failure • Arrhythmia/arrhythmia risk Psychosocial factors • Social isolation • Depression, stress, and anxiety • Sexual activity Multidisciplinary team follow-up • Cardiologist • Primary care • Advanced practice nurse/ physician assistant • Other relevant medical specialists • Other non-medical specialists (e.g. physiotherapist, psychologist, pharmacist, dietician, vocational specialist) Patient/family education • Plan of care • Education • Recognition of symptoms, signs and symptoms for urgent vs. emergency evaluations • Risk factor control • Activating EMS • CPR training for family members • Advanced directives Socioeconomic and healthcare factors • Access to health insurance coverage • Access to healthcare providers • Disability • Social services • Social networks • Community services • Electronic personal health records Interventions . Components . Risk factor modification/ lifestyle interventions • Healthy diet • Physical activity • Weight control • Smoking cessation • Stop alcohol abuse Preventive medications • Antithrombotic therapies • Beta-blockers • ACE inhibitors/ARBs/ aldosterone antagonists (if depressed left ventricular function) • Statins Management of comorbidities • Obesity • Dyslipidaemia • Arterial hypertension • Diabetes • Heart failure • Arrhythmia/arrhythmia risk Psychosocial factors • Social isolation • Depression, stress, and anxiety • Sexual activity Multidisciplinary team follow-up • Cardiologist • Primary care • Advanced practice nurse/ physician assistant • Other relevant medical specialists • Other non-medical specialists (e.g. physiotherapist, psychologist, pharmacist, dietician, vocational specialist) Patient/family education • Plan of care • Education • Recognition of symptoms, signs and symptoms for urgent vs. emergency evaluations • Risk factor control • Activating EMS • CPR training for family members • Advanced directives Socioeconomic and healthcare factors • Access to health insurance coverage • Access to healthcare providers • Disability • Social services • Social networks • Community services • Electronic personal health records ACI: acute myocardial infarction; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor inhibitors; CPR: cardiopulmonary resuscitation; EMS: emergency medical system. Open in new tab Table 1. Components of secondary prevention in post-AMI patients. Interventions . Components . Risk factor modification/ lifestyle interventions • Healthy diet • Physical activity • Weight control • Smoking cessation • Stop alcohol abuse Preventive medications • Antithrombotic therapies • Beta-blockers • ACE inhibitors/ARBs/ aldosterone antagonists (if depressed left ventricular function) • Statins Management of comorbidities • Obesity • Dyslipidaemia • Arterial hypertension • Diabetes • Heart failure • Arrhythmia/arrhythmia risk Psychosocial factors • Social isolation • Depression, stress, and anxiety • Sexual activity Multidisciplinary team follow-up • Cardiologist • Primary care • Advanced practice nurse/ physician assistant • Other relevant medical specialists • Other non-medical specialists (e.g. physiotherapist, psychologist, pharmacist, dietician, vocational specialist) Patient/family education • Plan of care • Education • Recognition of symptoms, signs and symptoms for urgent vs. emergency evaluations • Risk factor control • Activating EMS • CPR training for family members • Advanced directives Socioeconomic and healthcare factors • Access to health insurance coverage • Access to healthcare providers • Disability • Social services • Social networks • Community services • Electronic personal health records Interventions . Components . Risk factor modification/ lifestyle interventions • Healthy diet • Physical activity • Weight control • Smoking cessation • Stop alcohol abuse Preventive medications • Antithrombotic therapies • Beta-blockers • ACE inhibitors/ARBs/ aldosterone antagonists (if depressed left ventricular function) • Statins Management of comorbidities • Obesity • Dyslipidaemia • Arterial hypertension • Diabetes • Heart failure • Arrhythmia/arrhythmia risk Psychosocial factors • Social isolation • Depression, stress, and anxiety • Sexual activity Multidisciplinary team follow-up • Cardiologist • Primary care • Advanced practice nurse/ physician assistant • Other relevant medical specialists • Other non-medical specialists (e.g. physiotherapist, psychologist, pharmacist, dietician, vocational specialist) Patient/family education • Plan of care • Education • Recognition of symptoms, signs and symptoms for urgent vs. emergency evaluations • Risk factor control • Activating EMS • CPR training for family members • Advanced directives Socioeconomic and healthcare factors • Access to health insurance coverage • Access to healthcare providers • Disability • Social services • Social networks • Community services • Electronic personal health records ACI: acute myocardial infarction; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor inhibitors; CPR: cardiopulmonary resuscitation; EMS: emergency medical system. Open in new tab Although traditionally divided into three phases (e.g. inpatient, outpatient, long-term intervention), in reality secondary prevention is a continuous lifelong process, a care pathway that follows the patient journey, made up of key stages that need to occur to enable patients to achieve the return to a normal life.16 Settings vary in different countries,17 according to local and national regulations and experiences, involving residential, ambulatory community, or home-based programmes. While the objectives are identical to those for outpatients, residential inpatient programmes are specifically structured to provide more intensive and/or complex interventions, reserved for high-risk patients.18 Preventive services in the community offer the opportunity to maintain the benefits in the long term,19 with potential for overcoming existing barriers to healthcare such as distance, unfamiliarity and fear/distrust of hospitals, allowing the delivery of a programme that is best placed (i.e. ‘tailored’) to meet individual needs. EUROACTION20 and GOSPEL21 interventions provided scientific evidence for a beneficial long-term effect of community-based programmes. The EUROACTION study tested a comprehensive, nurse-led, family centred and multidisciplinary model of preventive and rehabilitative care in eight countries in Europe, and was subsequently set up as an integrated community centred service in the UK (MyAction) providing care for both vascular patients and those at high cardiovascular risk, while the GOSPEL study is an Italian long-term multifactorial educational and behavioral intervention (coordinated by a cardiologist) after a standard rehabilitation programme following AMI. The existing health-economic literature supports comprehensive secondary prevention as a relatively more cost-effective intervention in IHD patients, in comparison to invasive therapies or cardiac surgery.22 Given the current economic challenges in healthcare it is noteworthy that in low and middle-income countries, cardiac prevention has been demonstrated to be both effective and cost-effective.23 Identification of gaps and potential solutions in implementation Despite the availability of suitable secondary prevention programmes, only one third to one half of eligible patients are referred24 or finally take up a preventive programme.25 A plethora of research indicates that patient, healthcare provider and/or health system-based barriers all hold responsibility for this (Table 2).26 Table 2. Factors leading to therapeutic inertia in cardiovascular prevention, attributed to patient level, clinician/health care provider level and healthcare system level. Patient . Clinician/healthcare provider . Healthcare system . Medication side-effects Failure to initiate treatment Lack of clinical guideline Too many medications Failure to titrate to goal Lack of care coordination Cost of medications Failure to set clear goals No visit planning Denial of disease Underestimation of patient need Lack of decision support Denial of disease severity Failure to identify and manage comorbid conditions Poor communication between physician and others involved in a patient’s healthcare provision Forgetfulness Insufficient time No disease registry Perception of low susceptibility Insufficient focus of emphasis on goal attainment No active outreach Absence of disease symptoms Reactive rather than proactive Perverse incentives Poor communication with physician Poor communication skills Pressure to shorten length of hospital stay Mistrust of physician Shortage of time Healthcare systems focused on acute care (hospital-based health systems) Depression, mental disease, substance abuse Poor awareness on value of preventive measure Lack of preventive structure Low health literacy/poor awareness on value of preventive measure Poorly designed preventive programmes/lack of quality control Patient . Clinician/healthcare provider . Healthcare system . Medication side-effects Failure to initiate treatment Lack of clinical guideline Too many medications Failure to titrate to goal Lack of care coordination Cost of medications Failure to set clear goals No visit planning Denial of disease Underestimation of patient need Lack of decision support Denial of disease severity Failure to identify and manage comorbid conditions Poor communication between physician and others involved in a patient’s healthcare provision Forgetfulness Insufficient time No disease registry Perception of low susceptibility Insufficient focus of emphasis on goal attainment No active outreach Absence of disease symptoms Reactive rather than proactive Perverse incentives Poor communication with physician Poor communication skills Pressure to shorten length of hospital stay Mistrust of physician Shortage of time Healthcare systems focused on acute care (hospital-based health systems) Depression, mental disease, substance abuse Poor awareness on value of preventive measure Lack of preventive structure Low health literacy/poor awareness on value of preventive measure Poorly designed preventive programmes/lack of quality control Open in new tab Table 2. Factors leading to therapeutic inertia in cardiovascular prevention, attributed to patient level, clinician/health care provider level and healthcare system level. Patient . Clinician/healthcare provider . Healthcare system . Medication side-effects Failure to initiate treatment Lack of clinical guideline Too many medications Failure to titrate to goal Lack of care coordination Cost of medications Failure to set clear goals No visit planning Denial of disease Underestimation of patient need Lack of decision support Denial of disease severity Failure to identify and manage comorbid conditions Poor communication between physician and others involved in a patient’s healthcare provision Forgetfulness Insufficient time No disease registry Perception of low susceptibility Insufficient focus of emphasis on goal attainment No active outreach Absence of disease symptoms Reactive rather than proactive Perverse incentives Poor communication with physician Poor communication skills Pressure to shorten length of hospital stay Mistrust of physician Shortage of time Healthcare systems focused on acute care (hospital-based health systems) Depression, mental disease, substance abuse Poor awareness on value of preventive measure Lack of preventive structure Low health literacy/poor awareness on value of preventive measure Poorly designed preventive programmes/lack of quality control Patient . Clinician/healthcare provider . Healthcare system . Medication side-effects Failure to initiate treatment Lack of clinical guideline Too many medications Failure to titrate to goal Lack of care coordination Cost of medications Failure to set clear goals No visit planning Denial of disease Underestimation of patient need Lack of decision support Denial of disease severity Failure to identify and manage comorbid conditions Poor communication between physician and others involved in a patient’s healthcare provision Forgetfulness Insufficient time No disease registry Perception of low susceptibility Insufficient focus of emphasis on goal attainment No active outreach Absence of disease symptoms Reactive rather than proactive Perverse incentives Poor communication with physician Poor communication skills Pressure to shorten length of hospital stay Mistrust of physician Shortage of time Healthcare systems focused on acute care (hospital-based health systems) Depression, mental disease, substance abuse Poor awareness on value of preventive measure Lack of preventive structure Low health literacy/poor awareness on value of preventive measure Poorly designed preventive programmes/lack of quality control Open in new tab Patient-related gaps Education and empowerment Patients with IHD understand poorly their disease and perceive themselves as having little control over its course, many lack interest in prevention and/or feel embarrassed about participating in preventive group sessions. Most of them report not receiving robust information and/or encouragement from physicians and other health professionals regarding how to prevent recurrent events.27 Other factors, which hinder attendance, include lack of social support, poor psychological wellbeing, inconvenient location with transport difficulties, competing work commitments and financial cost.16 Inadequacies and time constraints related to education and counselling of patients before they leave hospital lead to deficiencies in implementation of preventive care later on. Patients who have a clear understanding of their after-hospital care instructions are 30% less likely to be readmitted or to visit the emergency department than patients who lack this information.28 Patients discharged from the hospital with a clear guideline-oriented treatment recommendation, a checklist of measures to ensure risk modification and lifestyle change provided in the discharge letter, educated to care for themselves and to know how or when to seek follow-up care, can better understand the importance of this information and its potential impact.29 A wide variety of techniques and combinations of techniques has also been evaluated, but only self-monitoring of physical activity and action planning or coping strategies targeting barriers seem to be helpful (Table 3).30 Table 3. Components of an optimal, standardised, patient-centred discharge process. • Creating a clear follow-up plan, coordinating appointments for clinician follow-up, post-discharge testing, and transportation arrangements • Giving the patient a written discharge plan at the time of discharge, explaining the reason for hospitalisation and information about medications • Assessing the patient’s understanding of his/her diagnosis, of the clinical tests and evaluations performed in the hospital, of the discharge plan, including medications, lifestyle changes, (in case, by asking the patient to explain the discharge plan in his or her own words in order to identify and resolve barriers to understanding) • Educating the patient about recognition of cardiac symptoms, problem-solving strategies, and review appointments plans • Providing hospital contact details, and telephone contacts after discharge to address concerns • Sending the discharge summary to the physicians and other services responsible for the patient’s care after discharge together with contact details of relatives and healthcare providers where appropriate • Creating a clear follow-up plan, coordinating appointments for clinician follow-up, post-discharge testing, and transportation arrangements • Giving the patient a written discharge plan at the time of discharge, explaining the reason for hospitalisation and information about medications • Assessing the patient’s understanding of his/her diagnosis, of the clinical tests and evaluations performed in the hospital, of the discharge plan, including medications, lifestyle changes, (in case, by asking the patient to explain the discharge plan in his or her own words in order to identify and resolve barriers to understanding) • Educating the patient about recognition of cardiac symptoms, problem-solving strategies, and review appointments plans • Providing hospital contact details, and telephone contacts after discharge to address concerns • Sending the discharge summary to the physicians and other services responsible for the patient’s care after discharge together with contact details of relatives and healthcare providers where appropriate Open in new tab Table 3. Components of an optimal, standardised, patient-centred discharge process. • Creating a clear follow-up plan, coordinating appointments for clinician follow-up, post-discharge testing, and transportation arrangements • Giving the patient a written discharge plan at the time of discharge, explaining the reason for hospitalisation and information about medications • Assessing the patient’s understanding of his/her diagnosis, of the clinical tests and evaluations performed in the hospital, of the discharge plan, including medications, lifestyle changes, (in case, by asking the patient to explain the discharge plan in his or her own words in order to identify and resolve barriers to understanding) • Educating the patient about recognition of cardiac symptoms, problem-solving strategies, and review appointments plans • Providing hospital contact details, and telephone contacts after discharge to address concerns • Sending the discharge summary to the physicians and other services responsible for the patient’s care after discharge together with contact details of relatives and healthcare providers where appropriate • Creating a clear follow-up plan, coordinating appointments for clinician follow-up, post-discharge testing, and transportation arrangements • Giving the patient a written discharge plan at the time of discharge, explaining the reason for hospitalisation and information about medications • Assessing the patient’s understanding of his/her diagnosis, of the clinical tests and evaluations performed in the hospital, of the discharge plan, including medications, lifestyle changes, (in case, by asking the patient to explain the discharge plan in his or her own words in order to identify and resolve barriers to understanding) • Educating the patient about recognition of cardiac symptoms, problem-solving strategies, and review appointments plans • Providing hospital contact details, and telephone contacts after discharge to address concerns • Sending the discharge summary to the physicians and other services responsible for the patient’s care after discharge together with contact details of relatives and healthcare providers where appropriate Open in new tab Adherence to healthy lifestyle interventions A systematic review and meta-analysis of adherence to cardioprotective medicines in more than 350,000 patients found low adherence in both individuals at high cardiovascular risk (66%) and in patients with cardiovascular disease (CVD) (50%) a median of two years after initiation of a prescription.31 This results in worse outcomes and higher healthcare costs.32,33 The reasons for non-adherence are complex and influenced by factors including demography, socioeconomic factors, health systems factors, intensity of follow-up, time since last provider visit, adverse effects of therapy, complex medication regimens and health literacy (Table 2). For these reasons, the healthcare provider should assess not only adherence to medication, but also identify reasons, and promote adherence according to established principles (Table 4). In this aspect, the active role of the pharmacist should be encouraged: in the UK, the new pharmacist-led medicines optimisation clinic is a model of implementation of the contribution of the pharmacist to support patients post-myocardial infarction (MI). Table 4. Adherence factors. • ‘Agree’ rather than ‘dictate’ a drug regimen and tailor it to personal lifestyle and needs • Provide advice regarding benefits and possible adverse effects of medications, and duration and timing of doses • Consider patients’ habits and preferences, encourage self-monitoring, use of cues and technologies to act as reminders • Reduce dosage demands to the lowest feasible level and simplify the dosing regimen when possible • Ask patients in a non-judgemental way how the medication works • Back up verbal instructions with clear written instructions • Implement repetitive monitoring and feedback and regular review of medicines to minimise polypharmacy • Introduce trained nurses or physician assistants if needed and feasible • Promoting the active role of the pharmacist in assessing drug adherence and in encouraging patients to discuss their medicines and any concerns they may have about them • Involve the partner, other family member or carer in the patient’s treatment • In case of persistent non-adherence, offer multisession or combined behavioural intervention • ‘Agree’ rather than ‘dictate’ a drug regimen and tailor it to personal lifestyle and needs • Provide advice regarding benefits and possible adverse effects of medications, and duration and timing of doses • Consider patients’ habits and preferences, encourage self-monitoring, use of cues and technologies to act as reminders • Reduce dosage demands to the lowest feasible level and simplify the dosing regimen when possible • Ask patients in a non-judgemental way how the medication works • Back up verbal instructions with clear written instructions • Implement repetitive monitoring and feedback and regular review of medicines to minimise polypharmacy • Introduce trained nurses or physician assistants if needed and feasible • Promoting the active role of the pharmacist in assessing drug adherence and in encouraging patients to discuss their medicines and any concerns they may have about them • Involve the partner, other family member or carer in the patient’s treatment • In case of persistent non-adherence, offer multisession or combined behavioural intervention Open in new tab Table 4. Adherence factors. • ‘Agree’ rather than ‘dictate’ a drug regimen and tailor it to personal lifestyle and needs • Provide advice regarding benefits and possible adverse effects of medications, and duration and timing of doses • Consider patients’ habits and preferences, encourage self-monitoring, use of cues and technologies to act as reminders • Reduce dosage demands to the lowest feasible level and simplify the dosing regimen when possible • Ask patients in a non-judgemental way how the medication works • Back up verbal instructions with clear written instructions • Implement repetitive monitoring and feedback and regular review of medicines to minimise polypharmacy • Introduce trained nurses or physician assistants if needed and feasible • Promoting the active role of the pharmacist in assessing drug adherence and in encouraging patients to discuss their medicines and any concerns they may have about them • Involve the partner, other family member or carer in the patient’s treatment • In case of persistent non-adherence, offer multisession or combined behavioural intervention • ‘Agree’ rather than ‘dictate’ a drug regimen and tailor it to personal lifestyle and needs • Provide advice regarding benefits and possible adverse effects of medications, and duration and timing of doses • Consider patients’ habits and preferences, encourage self-monitoring, use of cues and technologies to act as reminders • Reduce dosage demands to the lowest feasible level and simplify the dosing regimen when possible • Ask patients in a non-judgemental way how the medication works • Back up verbal instructions with clear written instructions • Implement repetitive monitoring and feedback and regular review of medicines to minimise polypharmacy • Introduce trained nurses or physician assistants if needed and feasible • Promoting the active role of the pharmacist in assessing drug adherence and in encouraging patients to discuss their medicines and any concerns they may have about them • Involve the partner, other family member or carer in the patient’s treatment • In case of persistent non-adherence, offer multisession or combined behavioural intervention Open in new tab A Cochrane review34 of interventions to improve medication adherence advised drawing on the support of allied professionals such as nurses and pharmacists to deliver complex interventions, which may include telephone follow-up, interim appointments and monitoring of repeat prescriptions. Drawing on the support of non-professional people within the social context of the patient, such as spouses, other family members, carers or other key figures, and lay groups in the community, may prove to be a cost-effective way to improve adherence. However, the review acknowledged that such interventions may be difficult to replicate in everyday clinical care due to cost and availability of personnel. Adherence to preventive pharmacological therapy Adherence to medication is low in individuals at high risk and in patients with CVD, resulting in worse outcomes and higher healthcare costs.11 Non-adherence is multifactorial and is influenced by demographic and socioeconomic factors, time since last provider visit, adverse effects of therapy and complex medication regimens (Table 2). For these reasons, the healthcare provider should assess not only adherence to medication, but also identify reasons, and promote adherence according to established principles35,36 (Table 4). Furthermore, the development in many patients of real or presumed ‘drug intolerance’ should be considered, and how quick the physicians label patient as such may severely disadvantage post-MI patients. The post-MI patients may also present with several comorbidities, which need multiple treatments, sometimes in conflict with each other. The role of the physician is also trying to simplify the treatment regimen to the lowest acceptable level, with repetitive monitoring and feedback. The use of the polypill and combination therapy to increase adherence to drug therapy may be considered. Finally, medicines optimisation may also mean de-prescribing: physicians should also evaluate when to stop and de-prescribe medicines: for example, there is National Institute for Health and Care Excellence (NICE) recommendation for stopping long-term beta-blockers post-MI in patients who do not have heart failure or other specific indication.37 Healthcare provider gaps Healthcare providers’ knowledge and motivation In the description of the core curriculum for the cardiologist, the European Society of Cardiology (ESC) defines in detail the knowledge needed in regard to secondary prevention, including evaluation and management of cardiovascular risk, as well as the provision of appropriate prevention to CVD patients.38 However, it is questionable whether such requirements are part of the curriculum of most cardiologists or specialist allied health professionals trained in Europe. This gap in knowledge and motivation also apply to general practitioners (GPs) and non-cardiology healthcare professionals and need to be closed, by specific educational training. Furthermore, for decades, much attention and many resources have been directed at encouraging physicians and providers to shift care as much as possible away from costly inpatient hospital stays towards less expensive outpatient treatment.39 Among the most important metrics for gauging the success of this endeavour is the shortening of the hospital length of stay, early discharge even directly from intensive care units, although real savings have not been proved.40 This leaves a limited amount of time for information and education. In addition, it does not allow for optimisation of risk stratification and secondary prevention therapy, particularly medication dose titration prior to hospital discharge. Risk stratification Risk stratification is the prerequisite for improving care management. Because the risk of events decreases with time, early assessment (e.g. infarct size and resting left ventricular function) is crucial before discharge.41 Current guidelines recommend evaluation of metabolic risk markers during the index admission, such as fitness level, body mass index, LDL cholesterol, fasting glucose level.13 Post-discharge plan Strategies effective to increase uptake include not only patient education and empowerment (see section on Education and empowerment above) but also, at post-hospital discharge, the development of gender-tailored sessions, structured follow-up via either telephone call or visit by a healthcare professional or both, a specific programme for older patients and planned early appointments to programmes.42–44 Awareness and communication among health professionals in acute care and in primary care The transfer of the specialist’s knowledge to the community team remains a major challenge, as only about half of the GPs use guidelines in everyday practice and knowledge of treatment goals is often insufficient.45 Delayed communication or inaccuracies in information transfer among healthcare professionals has substantial implications for continuity of care, patient safety, patient and clinician satisfaction and resource use.46 Educational meetings, audit and feedback, with local opinion leaders and access to computer decision support devices can lead to improved continuity of care.47 Regular review and provision of patient education in primary care leads to improved adherence to lifestyle advice (more physical activity, better diet), reduced symptoms, improved quality of life and reduced mortality.48 In the UK, the clinical indicators of GPs’ performance in chronic disease monitoring include checklists relating to medication and risk factor control, and engagement in this process is incentivised by financial reward.49 Healthcare systems gaps Patients consistently cite physicians and other healthcare providers as the main sources of encouragement for subsequent participation in preventive programmes.30 Unfortunately, several factors negatively influence current referral rates. Availability of structured secondary prevention programme The lack of prevention centres constitutes an obstacle to the implementation of rehabilitation programmes in many European areas but particularly in less advantaged regions.50 Referral to structured secondary prevention intervention Lack of referral is an important impediment to participation in preventive programmes. The presence of inter-hospital variability in referral rates suggests that several healthcare system factors might have a strong influence, including insurance coverage, hospital characteristics (dimension, geographical location) and other unidentified factors.50 Limited financial incentives for the physician to implement preventive measures and the pressures of competing workload priorities may negatively influence current referral rates.51 Various strategies can address the lack of referral and improve enrolment (Figure 1).52 Systematic processes such as automatic referral and liaison systems to connect cardiac patients with the preventive programme have been developed and can increase referral rates by more than 50%.53 Evidence is emerging to suggest that mechanisms to support automatic patient referral via electronic health records or discharge protocols are effective in increasing referral. Strength of physician endorsement for referring cardiac patients is a pivotal step to improve participation and its associated improved outcomes after AMI.53 Figure 1. Open in new tabDownload slide Strategies to address the lack of referral and improve enrolment in cardiovascular secondary prevention programme. Performance indicators The lack of benefit from some interventions (e.g. RAMIT trial)54 highlights the need for quality and minimum standards in the delivery of preventive programmes. Audit and control of the programmes should include information about the core components and their implementation, results with clinical outcomes and patient satisfaction. Benchmarking against local, regional and national standards provides measures of performance and quality for commissioners and services providers.15 Accountability measures, including referral performance/quality indicators (e.g. percentage of cardiac patients referred to programmes) and financial incentives for centres performing well on the quality indicators should increase physicians’ willingness to refer and improve the delivery of prevention. Furthermore, the appropriate prescription of evidence-based medications (e.g. lipid-lowering drugs, antiplatelets) the titration of vasodilators, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers are well recognised performance indicators.15 Table 5 enumerates some examples of interventions on a patient, provider and system level. Table 5. Examples of cardiovascular preventive intervention at patient, provider and system level (adapted from Nieuwlaat et al.47). Example of intervention . Description . Effect . Patient-level interventions Patient decision aids Tools that help people become involved in decision-making by providing information about the options and outcomes of a treatment, and clarifying personal values 60% increase in accuracy of patient’s risk perception 30% reduction in post-menopausal hormone use 20% reduction in discretionary surgery Self-management Patients monitoring themselves, and making medication dosing decisions, with healthcare provider back-up 49% reduction in thrombotic events in self-management of vitamin K antagonist 56% reduction in heart failure hospitalisations in self-management of heart failure Provider-level interventions Continuing education meetings Conferences, lectures, workshops, seminars, symposia, and courses for health professionals 6–10% increase in uptake of recommended care Audit and feedback Any summary of clinical performance over a specified period of time, given in a written, electronic or verbal format 5–16% increase in the uptake of recommended diagnostic and therapeutic strategies Educational outreach visits Visits by a trained person to health professionals. ‘Face-to-face’ visits, also referred to as academic detailing 5.6–21% increase in uptake of recommended care Local opinion leaders Healthcare professionals considered by colleagues as ‘educationally influential’ 12% increase in uptake of recommended care Computer-assisted clinical decision support Automated clinical decision advice, based on individual patient data Modest effects on process of care for a range of management issues Organizational/system-level interventions Clinical pathways Structured multidisciplinary care plans used by health services to detail essential steps in the care of patients with a specific clinical problem 42% reduction of in-hospital complications for patients undergoing an intervention, primarily surgery 12% improvement of documentation in medical records Financial incentives Financial reward for professionals for affecting behaviour, including for a specified time period of work; for each service, episode or visit; for a patient or specific population; for providing a prespecified level or providing a change in activity or quality of care Potential improvement in practice, but effects on patient outcomes are unknown Legislation-based smoking bans Legislative smoking bans and restrictions affecting populations Reduction in admissions for acute coronary syndromes, related to improvements in first-hand and second-hand smoking exposure Example of intervention . Description . Effect . Patient-level interventions Patient decision aids Tools that help people become involved in decision-making by providing information about the options and outcomes of a treatment, and clarifying personal values 60% increase in accuracy of patient’s risk perception 30% reduction in post-menopausal hormone use 20% reduction in discretionary surgery Self-management Patients monitoring themselves, and making medication dosing decisions, with healthcare provider back-up 49% reduction in thrombotic events in self-management of vitamin K antagonist 56% reduction in heart failure hospitalisations in self-management of heart failure Provider-level interventions Continuing education meetings Conferences, lectures, workshops, seminars, symposia, and courses for health professionals 6–10% increase in uptake of recommended care Audit and feedback Any summary of clinical performance over a specified period of time, given in a written, electronic or verbal format 5–16% increase in the uptake of recommended diagnostic and therapeutic strategies Educational outreach visits Visits by a trained person to health professionals. ‘Face-to-face’ visits, also referred to as academic detailing 5.6–21% increase in uptake of recommended care Local opinion leaders Healthcare professionals considered by colleagues as ‘educationally influential’ 12% increase in uptake of recommended care Computer-assisted clinical decision support Automated clinical decision advice, based on individual patient data Modest effects on process of care for a range of management issues Organizational/system-level interventions Clinical pathways Structured multidisciplinary care plans used by health services to detail essential steps in the care of patients with a specific clinical problem 42% reduction of in-hospital complications for patients undergoing an intervention, primarily surgery 12% improvement of documentation in medical records Financial incentives Financial reward for professionals for affecting behaviour, including for a specified time period of work; for each service, episode or visit; for a patient or specific population; for providing a prespecified level or providing a change in activity or quality of care Potential improvement in practice, but effects on patient outcomes are unknown Legislation-based smoking bans Legislative smoking bans and restrictions affecting populations Reduction in admissions for acute coronary syndromes, related to improvements in first-hand and second-hand smoking exposure Open in new tab Table 5. Examples of cardiovascular preventive intervention at patient, provider and system level (adapted from Nieuwlaat et al.47). Example of intervention . Description . Effect . Patient-level interventions Patient decision aids Tools that help people become involved in decision-making by providing information about the options and outcomes of a treatment, and clarifying personal values 60% increase in accuracy of patient’s risk perception 30% reduction in post-menopausal hormone use 20% reduction in discretionary surgery Self-management Patients monitoring themselves, and making medication dosing decisions, with healthcare provider back-up 49% reduction in thrombotic events in self-management of vitamin K antagonist 56% reduction in heart failure hospitalisations in self-management of heart failure Provider-level interventions Continuing education meetings Conferences, lectures, workshops, seminars, symposia, and courses for health professionals 6–10% increase in uptake of recommended care Audit and feedback Any summary of clinical performance over a specified period of time, given in a written, electronic or verbal format 5–16% increase in the uptake of recommended diagnostic and therapeutic strategies Educational outreach visits Visits by a trained person to health professionals. ‘Face-to-face’ visits, also referred to as academic detailing 5.6–21% increase in uptake of recommended care Local opinion leaders Healthcare professionals considered by colleagues as ‘educationally influential’ 12% increase in uptake of recommended care Computer-assisted clinical decision support Automated clinical decision advice, based on individual patient data Modest effects on process of care for a range of management issues Organizational/system-level interventions Clinical pathways Structured multidisciplinary care plans used by health services to detail essential steps in the care of patients with a specific clinical problem 42% reduction of in-hospital complications for patients undergoing an intervention, primarily surgery 12% improvement of documentation in medical records Financial incentives Financial reward for professionals for affecting behaviour, including for a specified time period of work; for each service, episode or visit; for a patient or specific population; for providing a prespecified level or providing a change in activity or quality of care Potential improvement in practice, but effects on patient outcomes are unknown Legislation-based smoking bans Legislative smoking bans and restrictions affecting populations Reduction in admissions for acute coronary syndromes, related to improvements in first-hand and second-hand smoking exposure Example of intervention . Description . Effect . Patient-level interventions Patient decision aids Tools that help people become involved in decision-making by providing information about the options and outcomes of a treatment, and clarifying personal values 60% increase in accuracy of patient’s risk perception 30% reduction in post-menopausal hormone use 20% reduction in discretionary surgery Self-management Patients monitoring themselves, and making medication dosing decisions, with healthcare provider back-up 49% reduction in thrombotic events in self-management of vitamin K antagonist 56% reduction in heart failure hospitalisations in self-management of heart failure Provider-level interventions Continuing education meetings Conferences, lectures, workshops, seminars, symposia, and courses for health professionals 6–10% increase in uptake of recommended care Audit and feedback Any summary of clinical performance over a specified period of time, given in a written, electronic or verbal format 5–16% increase in the uptake of recommended diagnostic and therapeutic strategies Educational outreach visits Visits by a trained person to health professionals. ‘Face-to-face’ visits, also referred to as academic detailing 5.6–21% increase in uptake of recommended care Local opinion leaders Healthcare professionals considered by colleagues as ‘educationally influential’ 12% increase in uptake of recommended care Computer-assisted clinical decision support Automated clinical decision advice, based on individual patient data Modest effects on process of care for a range of management issues Organizational/system-level interventions Clinical pathways Structured multidisciplinary care plans used by health services to detail essential steps in the care of patients with a specific clinical problem 42% reduction of in-hospital complications for patients undergoing an intervention, primarily surgery 12% improvement of documentation in medical records Financial incentives Financial reward for professionals for affecting behaviour, including for a specified time period of work; for each service, episode or visit; for a patient or specific population; for providing a prespecified level or providing a change in activity or quality of care Potential improvement in practice, but effects on patient outcomes are unknown Legislation-based smoking bans Legislative smoking bans and restrictions affecting populations Reduction in admissions for acute coronary syndromes, related to improvements in first-hand and second-hand smoking exposure Open in new tab The way ahead: embracing current challenges In-hospital or acute intervention This represents the earliest intervention, beginning immediately after the acute event during the hospital stay, and it should be given as high a priority as initial acute care. Acknowledging the formally shared responsibilities of all professionals involved in the cardiac patient’s care (i.e. nurses, GPs, intensivists, acute invasive cardiologists and cardiovascular surgeons) provides the first avenue. However, convincing all acute care clinicians remains challenging and is related to both the individual professional and the healthcare organisation.55 Poor knowledge regarding the benefits of the early initiation of secondary prevention could be a possible explanation. This underscores the need to increase awareness and to provide information regarding the available evidence. As a collaborative initiative, the European Association for Cardiovascular Prevention and Rehabilitation (EACPR), Acute Cardiovascular Care Association (ACCA) and Council on Cardiovascular Nursing and Allied Professions (CCNAP) elaborated videos on the benefits and challenges of secondary prevention after AMI (http://escardio.org/The-ESC/Communities/European-Association-for-Cardiovascular-Prevention-&-Rehabilitation-%28EACPR%29/European-Association-for-Cardiovascular-Prevention-Rehabilitation). Early outpatient prevention programmes: core delivery rehabilitation As mentioned above, patient uptake and adherence proves to be particularly challenging, and innovative strategies are urgently needed to address this problem. There are clearly some programmes that do better than others, at engaging patients in prevention, which creates a further opportunity to learn from others in regional or clinical networks. Telecommunication technologies Recent developments in telecommunications have enabled the advent of new preventive delivery strategies, supplementing conventional centre-based services to expand their capabilities and to address the broad and extensive range of barriers preventing cardiac patients from participating. As such, cardiac telemedicine was introduced, that is, a comprehensive mHealth mode of care delivery, as a personalised prevention tool for cardiac patients to manage their own recovery and to prevent recurrent events remotely.56 The optimal programme consists of several modules devoted to monitoring, coaching, e-learning, social interaction and two-way communication with the caregiver.57 Adapted preventive programmes and community services Adapted preventive cardiology programmes, such as nurse-coordinated and family-based care, can be valuable alternatives to traditional inpatient and/or outpatient programmes.20 Professionals in primary care are essential for this task as they often have detailed knowledge of an individual’s social, medical and/or cultural background. This applies especially for the disadvantaged groups (poor, less educated and older people), who are most likely to drop out. New models of individualised interventions Efforts are waged to individualise programmes based on patient stratification to maximise clinical benefit and optimise safety. This can be achieved by prescribing patient-specific and tailored programmes, based on differing combinations of cardiovascular risk factors, underlying cardiac disease processes and/or exercise modifiers. Currently, the EXPERT (EXercise Prescription in Everyday practice & Rehabilitative Training) flowchart project, combining the collaborative work and knowledge of more than 35 experts (out of 11 European countries) in the rehabilitation of chronic internal diseases is being elaborated. It aims to aid future physicians in defining such individualised training programmes, based on the existing guidelines and position papers for different patient populations.58 Focus on the identification of frailty syndrome post-AMI and high-risk patients Patients with frailty syndrome, that is, older than 65 years, characterised by vulnerability to stress-related factors and a decrease in physiological reserves,59 suffer more often from AMI (15.4% vs. 7.4%), with increased mortality and hospitalisation risk after the index cardiac event.60 Future efforts need to focus on improved frailty identification, and to adapt/intensify prevention programmes, by adjusting medical therapies, modifying dosages and rehabilitative protocols. Several prognostic scores were developed specifically to identify the post-AMI patients being at highest risk for future adverse events (the Global Registry of Acute Coronary Events (GRACE) score and ACHTUNG-Rule).61 Long-term prevention Long-term adherence to healthy lifestyles and medications It constitutes a joint lifelong effort of patient, primary care physician, nurse, therapist and cardiologist. In this era of an ever increasing CVD epidemic, most current cardiac centres do not have the capacity to deliver long-term supervised and centre-based prevention to all eligible patients. One model might be to transfer resources from short-duration residential services to longer-duration outpatient services of lesser intensity, designed for lower-risk patients, but of larger number. A successful example already implemented in routine clinical practice for low-risk patients is the EUROACTION model: all aspects of a healthy lifestyle, comprehensive risk factor management and appropriate use of cardioprotective drugs are addressed, without the use of specialised hospital or community facilities.20 In other countries, such as Italy, sport-medicine specialists, operating in selected community-based sport medicine centres, in collaboration with specially trained physiotherapists, have developed dedicated programmes for exercise-based rehabilitation, follow-up and care in low-risk patients. Home-based programmes can be equally effective as centre based62 and tele-interventions can be efficacious in both the medium and long term, encouraging large-scale deployment of innovative models of care delivery.63 Finally, a fixed dose combination tablet (also called polypill) was shown to improve adherence compared to separate medications.64 However, potential adverse effects of a single drug component cannot be specifically corrected and therefore may also affect the treatment adherence to the other components. Pharmacological strategies to strengthen long-term secondary prevention Recent progress in drug strategies have widened the possibility in CVD prevention. Three issues in particular are considered here: (a) enhanced lipid-lowering therapy in addition to statins, according to the evidence of the efficacy of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9)65 and of the ezetimibe added therapy;66 (b) enhanced antithrombotic therapy in which new options have been demonstrated to be particularly effective in further reducing coronary events, such as prolonged up to 30 months (in contrast to recommended 12 months) after acute coronary events dual antiplatelet therapy (DAPT),67 and in particular the combination of aspirin and ticagrelor,68 and the addition of new anticoagulants, such as rivaroxaban, to DAPT;69 (c) enhanced blood pressure control to improve outcome, as shown by new strategies involving spironolactone add-on therapy in resistant hypertension,70 amiloride plus hydrochlorothiazide in patients requiring a diuretic71 and finally by a research protocol in which a lower blood pressure target of 120 mmHg in patients at high cardiovascular risk was associated with higher survival.72 These advances open new possibilities in long-term secondary prevention after AMI. However, the cost is high, from both a clinical perspective (potential serious side-effects) and from an economic perspective, to make it unlikely that these pharmacological strategies will be widely indicated for reducing residual risk in the near future. For this reason, identification of the highest-risk patients is pertinent, that is, those who are most likely to benefit from very intense preventive therapy. Moving forward and improving care delivery The role of the government National legislation regarding preventive programmes is absent in 54 % of the participating countries to the European Cardiac Rehabilitation Inventory Survey (ECRIS).17 Legislation provides an imperative to make available and to optimise services, and needs to be extended to all countries if citizens of Europe are to be treated equitably. The national societies of cardiology are therefore encouraged to lobby their respective governments to promote this. The role of the ESC in relation to advocacy at a European level is crucial for setting standards and for promoting good practice among its members. The role of the health insurance industry As noted by ECRIS, in 46% of European countries, patients covered the total cost for the long-term intervention, while in 18% of countries, patients received a small financial support from patient clubs and private health insurance companies. Given the well established clinical benefits of the long-term persistence of a healthy lifestyle in secondary prevention, efforts to convince the health insurance industry to support long-term prevention programmes are justified. Higher reimbursement to systems that provide high-value evidence-based care and incentives for individuals with persistent adherence to healthy lifestyle changes should be encouraged. The role of professional organisations Numerous professional national and European-wide organisations such as the ESC, EACPR, ACCA and CCNAP are committed to the different facets of secondary prevention after AMI. They have an important cross-fertilising role in sharing expertise and in supporting colleagues to develop better services. By collaborative efforts in establishing professional guidelines, cutting-edge scientific research and implementing initiatives that encourage good clinical practice; they play a pivotal role in assuring the flourishing of secondary prevention. As an example, the EACPR, the ESC and the Heart Failure Association of the ESC support the preventive cardiology, sports cardiology and exercise based rehabilitation – from set-up to new frontiers course (https://www.escardio.org/static_file/Escardio/Subspecialty/HFA/Education/EACPR_HFA_Exercise%20Training%20Programme%202015.pdf). This course enabled secondary prevention experts to accelerate their knowledge sharing with colleagues in the field. Need for further research Future research should focus on cost-effectiveness evaluations of novel care delivery strategies, to inform policy makers how limited healthcare resources should be allocated. Each nation and European partners should look to audit their own services against clinical minimum standards in delivery and outcomes. The development of action plans by the different individual stakeholders to move forward and improve care delivery is urgently needed. Author contribution MFP and UC contributed to the conception and design of the work and drafted the manuscript. All authors critically revised the manuscript and gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy. Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Piepoli reports having received consulting/speaking fees from Novartis and Servier. Dr. Bueno reports having received consulting/speaking fees from Abbott, Astra-Zeneca, Bayer, BMS-Pfizer, Daichii-Sankyo, Eli-Lilly, Ferrer, Novartis, Servier, and research grants from Astra-Zeneca. This document was produced in the framework of the ESC Secondary Prevention after Myocardial Infarction Programme, developed by the European Association for Cardiovascular Prevention and Rehabilitation (EACPR), the Acute Cardiovascular Care Association (ACCA) and the Council on Cardiovascular Nursing and Allied Professions (CCNAP). Funding The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: This paper was produced in the framework of the ESC Prevention of CVD Programme, led by the European Association for Cardiovascular Prevention and Rehabilitation (EACPR) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Council on Cardiovascular Nursing and Allied Professions (CCNAP), which is supported by unrestricted educational grants. The author(s) received no financial support for the research, authorship, and/or publication of this article. References 1 White HD , Chew DP. Acute myocardial infarction . Lancet 2008 ; 372 ( 9638 ): 570 – 584 . Google Scholar Crossref Search ADS PubMed WorldCat 2 Smolina K , Wright FL, Rayner Met al. . Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study . BMJ 2012 ; 344 : d8059 – d8059 . Google Scholar Crossref Search ADS PubMed WorldCat 3 Pedersen F , Butrymovich V, Kelbaek Het al. . Short- and long-term cause of death in patients treated with primary PCI for STEMI . J Am Coll Cardiol 2014 ; 64 : 2101 – 2108 . Google Scholar Crossref Search ADS PubMed WorldCat 4 Velders MA , James SK, Libungan Bet al. . Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry . Am Heart J 2014 ; 167 : 666 – 673 . Google Scholar Crossref Search ADS PubMed WorldCat 5 Jernberg T , Hasvold P, Henriksson Met al. . Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective . Eur Heart J 2015 ; 36 : 1163 – 1170 . Google Scholar Crossref Search ADS PubMed WorldCat 6 Kontis V , Mathers CD, Bonita Ret al. . Regional contributions of six preventable risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study . Lancet Glob Health . Epub ahead of print 20 October 2015. DOI: 10.1016/S2214-109X(15)00179-5 . OpenURL Placeholder Text WorldCat 7 Wilson K , Gibson N, Willan Aet al. . Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies . Arch Intern Med 2000 ; 160 : 939 – 944 . Google Scholar Crossref Search ADS PubMed WorldCat 8 Estruch R , Ros E, Salas-Salvadó Jet al. . PREDIMED Study Investigators . Primary prevention of cardiovascular disease with a Mediterranean diet . N Engl J Med 2013 ; 368 : 1279 – 1290 . Google Scholar Crossref Search ADS PubMed WorldCat 9 Yusuf S , Hawken S, Ounpuu Set al. . INTERHEART Study Investigators . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study . Lancet 2004 ; 364 ( 9438 ): 937 – 952 . Google Scholar Crossref Search ADS PubMed WorldCat 10 Chow CK , Jolly S, Rao-Melacini Pet al. . Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes . Circulation 2010 ; 121 : 750 – 758 . Google Scholar Crossref Search ADS PubMed WorldCat 11 Kotseva K , Wood D, De Bacquer Det al. . on behalf of the EUROASPIRE Investigators . EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries . Eur J Prev Cardiol . Epub ahead of print 15 April 2016. pii: 2047487316645474 . OpenURL Placeholder Text WorldCat 12 Urbinati S , Olivari Z, Gonzini Let al. . for the BLITZ-4 Investigators . Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry . Eur J Prev Cardiol 2015 ; 22 : 1548 – 1556 . Google Scholar Crossref Search ADS PubMed WorldCat 13 Perk J , De Backer G, Gohlke Het al. . European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) . Eur Heart J 2012 ; 33 : 1635 – 1701 . Google Scholar Crossref Search ADS PubMed WorldCat 14 Piepoli MF , Corrà U, Benzer Wet al. . Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation . Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation . Eur J Cardiovasc Prev Rehabil 2010 ; 17 : 1 – 17 . Google Scholar Crossref Search ADS PubMed WorldCat 15 Piepoli MF , Corrà U, Adamopoulos Set al. . Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery. A policy statement from the Cardiac Rehabilitation Section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology . Eur J Prev Cardiol 2012 ; 21 : 664 – 681 . Google Scholar Crossref Search ADS PubMed WorldCat 16 Dalal HM , Doherty P, Taylor RS. Cardiac rehabilitation . BMJ 2015 ; 351 : h5000 – h5000 . Google Scholar Crossref Search ADS PubMed WorldCat 17 Bjarnason-Wehrens B , McGee H, Zwisler ADet al. . Cardiac Rehabilitation Section European Association of Cardiovascular Prevention and Rehabilitation . Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey . Eur J Cardiovasc Prev Rehabil 2010 ; 17 : 410 – 418 . Google Scholar Crossref Search ADS PubMed WorldCat 18 Voller H , Reibis R, Schwaab Bet al. . The ESC Textbook of Preventive Cardiology, Part 4. Setting and delivery of preventive cardiology. Hospital-based rehabilitation units , Oxford : Oxford University Press , 2015 , pp. 285 – 293 . Google Scholar Google Preview OpenURL Placeholder Text WorldCat COPAC 19 Connolly S , Cupples M. The ESC Textbook of Preventive Cardiology, Part 4. Setting and delivery of preventive cardiology. Community-based prevention centres , Oxford : Oxford University Press , 2015 , pp. 312 – 319 . Google Scholar Google Preview OpenURL Placeholder Text WorldCat COPAC 20 Wood DA , Kotseva K, Connolly Set al. . on behalf of the EUROACTION Study Group . EUROACTION: a European Society of Cardiology demonstration project in preventive cardiology. A paired cluster randomised controlled trial of a multi-disciplinary family based preventive cardiology programme for coronary patients and asymptomatic high risk individuals . Lancet 2008 ; 371 : 1999 – 2012 . Google Scholar Crossref Search ADS PubMed WorldCat 21 Giannuzzi P , Temporelli PL, Marchioli Ret al. . Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network . Arch Intern Med 2008 ; 168 : 2194 – 2204 . Google Scholar Crossref Search ADS PubMed WorldCat 22 Fidan D1 , Unal B, Critchley Jet al. . Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010 . Q J Med 2007 ; 100(5) : 277 – 289 . Google Scholar Crossref Search ADS WorldCat 23 Oldridge NB, Pakosh MT and Thomas RJ. Cardiac rehabilitation in low- and middle-income countries: a review on cost and cost-effectiveness. Int Health 2016; 8: 77–82 . 24 Brown T , Hernandez A, Bittner Vet al. . Predictors of cardiac rehabilitation referral in coronary artery disease patients . J Am Coll Cardiol 2009 ; 54 : 515 – 521 . Google Scholar Crossref Search ADS PubMed WorldCat 25 Karmali KN , Davies P, Taylor Fet al. . Promoting patient uptake and adherence in cardiac rehabilitation . Cochrane Database Syst Rev 2014 ; 6 : CD007131 – CD007131 . Google Scholar OpenURL Placeholder Text WorldCat 26 Clark A , King-Shier K, Duncan Aet al. . Factors influencing referral to cardiac rehabilitation and secondary prevention programs: a systematic review . Eur J Prev Cardiol 2012 ; 20 : 692 – 700 . Google Scholar Crossref Search ADS WorldCat 27 McCorry NK , Corrigan M, Tully MAet al. . Perceptions of exercise among people who have not attended cardiac rehabilitation following myocardial infarction . J Health Psychol 2009 ; 14 : 924 – 932 . Google Scholar Crossref Search ADS PubMed WorldCat 28 Jack BW , Chetty VK, Anthony Det al. . A reengineered hospital discharge program to decrease rehospitalization: a randomized trial . Ann Intern Med 2009 ; 150 : 178 – 187 . Google Scholar Crossref Search ADS PubMed WorldCat 29 Piepoli MF , Corrà U, Abreu Aet al. . Cardiac Rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation of the ESC. Challenges in secondary prevention of cardiovascular diseases: a review of the current practice . Int J Cardiol 2015 ; 180 : 114 – 119 . Google Scholar Crossref Search ADS PubMed WorldCat 30 Cole JA , Smith SM, Hart Net al. . Do practitioners and friends support patients with coronary heart disease in lifestyle change? A qualitative study . BMC Fam Pract 2013 ; 14 : 126 – 126 . Google Scholar Crossref Search ADS PubMed WorldCat 31 Naderi SH , Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients . Am J Med 2012 ; 125 : 882 – 887 . Google Scholar Crossref Search ADS PubMed WorldCat 32 Corrao G , Conti V, Merlino Let al. . Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy . Clin Ther 2010 ; 32 : 300 – 310 . Google Scholar Crossref Search ADS PubMed WorldCat 33 Aubert RE , Yao J, Xia Fet al. . Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care 2010 ; 16 : 459 – 466 . Google Scholar PubMed OpenURL Placeholder Text WorldCat 34 Nieuwlaat R , Wilczynski N, Navarro Tet al. . Interventions for enhancing medication adherence . Cochrane Database Syst Rev 2014 ; 11 : CD000011 – CD000011 . Google Scholar OpenURL Placeholder Text WorldCat 35 National Institute for Health and Care Excellence. Medicine optimisation: the safe and effective use of medicines to enable the best possible outcomes, www.nice.org.uk/guidance/ng5 (accessed 4 March 2015) . 36 World Health Organization. Adherence to long-term therapies, Evidence for action. Geneva: WHO, http://who.int/chp/knowledge/publications/adherence_full_report.pdf (accessed 4 March 2015) . 37 National Institute for Health and Care Excellence. Myocardial infarction: cardiac rehabilitation and prevention of further MI. Clinical guideline, www.nice.org.uk/guidance/cg172 (accessed 4 March 2015) . 38 Gillebert TC , Brooks N, Fontes-Carvalho Ret al. . ESC Core Curriculum for the General Cardiologist (2013) . Eur Heart J 2013 ; 34 : 2381 – 2411 . Google Scholar Crossref Search ADS PubMed WorldCat 39 OECD. Length of hospital stay, https://data.oecd.org/healthcare/length-of-hospital-stay.htm (accessed 4 March 2015) . 40 Taheri PA , Butz DA, Greenfield LJ. Length of stay has minimal impact on the cost of hospital admission . J Am Coll Surg 2000 ; 191 : 123 – 130 . Google Scholar Crossref Search ADS PubMed WorldCat 41 Steg PG , James SK, Atar Det al. . Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) . ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation . Eur Heart J 2012 ; 33 : 2569 – 2619 . Google Scholar Crossref Search ADS PubMed WorldCat 42 Mercado MG , Smith DK, McConnon ML. Myocardial infarction: management of the subacute period . Am Family Physician 2013 ; 88 : 581 – 588 . Google Scholar OpenURL Placeholder Text WorldCat 43 Jack BW , Chetty VK, Anthony Det al. . A reengineered hospital discharge program to decrease rehospitalization: a randomized trial . Ann Intern Med 2009 ; 150 : 178 – 187 . Google Scholar Crossref Search ADS PubMed WorldCat 44 Clancy CM . Reengineering hospital discharge: a protocol to improve patient safety, reduce costs, and boost patient satisfaction . Am J Med Qual 2009 ; 24 : 344 – 346 . Google Scholar Crossref Search ADS PubMed WorldCat 45 Wachter RM , Goldman L. The hospitalist movement 5 years later . JAMA 2002 ; 287 : 487 – 494 . Google Scholar Crossref Search ADS PubMed WorldCat 46 Coleman EA , Min SJ, Chomiak Aet al. . Posthospital care transitions: patterns, complications, and risk identification . Health Serv Res 2004 ; 39 : 1449 – 1465 . Google Scholar Crossref Search ADS PubMed WorldCat 47 Nieuwlaat R , Schwalm JD, Khatib Ret al. . Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J 2013 ; 34 : 1262 – 1269 . Google Scholar Crossref Search ADS PubMed WorldCat 48 Cupples ME , McKnight A. A five year follow-up study of patients at high cardiovascular risk who took part in a randomised controlled trial of health promotion . BMJ 1999 ; 319 : 687 – 688 . Google Scholar Crossref Search ADS PubMed WorldCat 49 Health & Social Care Information Centre. Quality and outcomes framework, http://www.hscic.gov.uk/qof (accessed 4 March 2015) . 50 Piepoli MF , Binno S, Corrà Uet al. . Committee on Exercise Physiology & Training of the Heart Failure Association of the ESC . ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients . Eur J Heart Fail 2015 ; 17 : 631 – 638 . Google Scholar Crossref Search ADS PubMed WorldCat 51 Hobbs FD , Jukema JW, Da Silva PMet al. . Barriers to cardiovascular disease risk scoring and primary prevention in Europe . Q J Med 2010 ; 103 : 727 – 739 . Google Scholar Crossref Search ADS WorldCat 52 Thomas R , Denna T. The role of cardiac rehabilitation following acute coronary syndromes . Curr Cardiol Rep 2014 ; 16 : 534 – 534 . Google Scholar Crossref Search ADS PubMed WorldCat 53 Grace S , Russell K, Reid Ret al. . Effect of cardiac rehabilitation referral strategies on utilization rates: a prospective, controlled study . Arch Intern Med 2011 ; 171 : 235 – 241 . Google Scholar Crossref Search ADS PubMed WorldCat 54 West RR , Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction . Heart 2012 ; 98 : 637 – 644 . Google Scholar Crossref Search ADS PubMed WorldCat 55 Cabana MD , Rand CS, Powe NRet al. . Why don’t physicians follow clinical practice guidelines? A framework for improvement . JAMA 1999 ; 282 : 1458 – 1465 . Google Scholar Crossref Search ADS PubMed WorldCat 56 Frederix I , Vanhees L, Dendale Pet al. . A review of telerehabilitation for cardiac patients . J Telemed Telecare 2015 ; 21(1) : 45 – 53 . Google Scholar Crossref Search ADS WorldCat 57 Frederix I , Hansen D, Coninx Ket al. . Medium-term effectiveness of a comprehensive internet-based and patient-specific telerehabilitation program with text messaging support for cardiac patients: randomized controlled trial . J Med Internet Res 2015 ; 17 : e185 – e185 . Google Scholar Crossref Search ADS PubMed WorldCat 58 The EACPR Expert Flowchart Project. http://www.escardio.org/The-ESC/Communities/European-Association-for-Cardiovascular-Prevention-&-Rehabilitation-(EACPR)/News/The-EACPR-EXPERT-Flowchart-Project . 59 Myers V , Drory Y, Gerber Y. Clinical relevance of frailty trajectory post myocardial infarction . Eur J Prev Cardiol 2014 ; 21 : 758 – 766 . Google Scholar Crossref Search ADS PubMed WorldCat 60 Uchmanowicz I , Lisiak M, Wontor Ret al. . Frailty syndrome in cardiovascular disease: clinical significance and research tools . Eur J Cardiovasc Nurs 2015 ; 14 : 303 – 309 . Google Scholar Crossref Search ADS PubMed WorldCat 61 Barra S , Providencia R, Paiva Let al. . ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction . Eur Heart J Acute Cardiovasc Care 2012 ; 1 : 320 – 336 . Google Scholar Crossref Search ADS PubMed WorldCat 62 Taylor RS, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No.: CD007130. DOI: 10.1002/14651858.CD007130.pub3 . 63 Frederix I , Hansen D, Coninx Ket al. . Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: a cost-effectiveness analysis . Eur J Prev Cardiol . 23 : 674 – 682 . Crossref Search ADS PubMed WorldCat 64 Castellano JM , Sanz G, Peñalvo JLet al. . A polypill strategy to improve adherence: results from the FOCUS project . J Am Coll Cardiol 2014 ; 64 : 2071 – 2082 . Google Scholar Crossref Search ADS PubMed WorldCat 65 Colhoun HM , Robinson JG, Farnier Met al. . Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials . BMC Cardiovasc Disord 2014 ; 14 : 121 – 121 . Google Scholar Crossref Search ADS PubMed WorldCat 66 Cannon CP , Blazing MA, Giugliano RPet al. . for the IMPROVE-IT Investigators . Ezetimibe added to statin therapy after acute coronary syndromes . N Engl J Med 2015 ; 372 : 2387 – 2397 . Google Scholar Crossref Search ADS PubMed WorldCat 67 Mauri L , Kereiakes DJ, Yeh RWet al. . DAPT Study Investigators . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents . N Engl J Med 2014 ; 371 : 2155 – 2166 . Google Scholar Crossref Search ADS PubMed WorldCat 68 Bonaca MP , Bhatt DL, Cohen Met al. . PEGASUS TIMI 54 Steering Committee and Investigators . Long-term use of ticagrelor in patients with prior myocardial infarction . N Engl J Med 2015 ; 372 : 1791 – 1800 . Google Scholar Crossref Search ADS PubMed WorldCat 69 Mega JL , Braunwald E, Wiviott SDet al. . Rivaroxaban in patients with a recent acute coronary syndrome . N Engl J Med 2012 ; 366 : 9 – 19 . Google Scholar Crossref Search ADS PubMed WorldCat 70 Williams B , MacDonald TM, Morant Set al. . for The British Hypertension Society’s PATHWAY Studies Group . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial . Lancet 2015 ; 386 : 2059 – 2068 . Google Scholar Crossref Search ADS PubMed WorldCat 71 Brown MJ , Williams B, MacDonald TMet al. . Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomized double-blind trial in patients with essential hypertension . BMJ Open 2015 ; 5 : e008086 – e008086 . Google Scholar Crossref Search ADS PubMed WorldCat 72 The SPRINT Research Group . A randomized trial of intensive versus standard blood-pressure control . N Engl J Med 2015 ; 373 : 2103 – 2116 . Crossref Search ADS PubMed WorldCat Author notes This article is being co-published in the following journals: European Journal of Preventive Cardiology, European Heart Journal - Acute Cardiovascular Care and European Journal of Cardiovascular Nursing. To request permission to re-use any part of this article, please contact SAGE Publishing: http://online.sagepub.com/ © The European Society of Cardiology 2016 This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) © The European Society of Cardiology 2016
TI - Challenges in secondary prevention after acute myocardial infarction: A call for action
JF - European Journal of Preventive Cardiology
DO - 10.1177/2047487316663873
DA - 2016-12-01
UR - https://www.deepdyve.com/lp/oxford-university-press/challenges-in-secondary-prevention-after-acute-myocardial-infarction-a-4LpSPn0KMB
SP - 1994
EP - 2006
VL - 23
IS - 18
DP - DeepDyve
ER -